Skip to Content


Active Substance: dinutuximab
Common Name: dinutuximab
ATC Code: L01XC
Marketing Authorisation Holder: United Therapeutics Europe Ltd
Active Substance: dinutuximab
Status: Withdrawn
Authorisation Date: 2015-08-14
Therapeutic Area: Neuroblastoma
Pharmacotherapeutic Group: Antineoplastic agents

Therapeutic Indication

Unituxin is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months to 17years, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation (ASCT). It is administered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and isotretinoin.

The marketing authorisation for Unituxin has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.